You just read:

Celator® Pharmaceuticals Announces New Data for VYXEOS™ in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented at the American Association for Cancer Research Annual Meeting

News provided by

Celator Pharmaceuticals, Inc.

Mar 31, 2016, 07:00 ET